| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 77 |
| 1 | NIVOLUMAB | 66 |
| 2 | IPILIMUMAB | 51 |
| 3 | PACLITAXEL | 28 |
| 4 | PACLITAXEL (AIBUMIN-BOUND) | 28 |
| 5 | BEVACIZUMAB | 22 |
| 6 | CARBOPLATIN | 17 |
| 7 | PEMETREXED DISODIUM | 7 |
| 8 | ATEZOLIZUMAB | 5 |
| 9 | CYCLOPHOSPHAMIDE | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 1 | IPILIMUMAB | 51 | 0.0012 |
| 2 | PEMBROLIZUMAB | 77 | 0.0007 |
| 3 | NIVOLUMAB | 66 | 0.0007 |
| 4 | LEVOLEUCOVORIN INJECTION | 2 | 0.0007 |
| 5 | LEVOLEUCOVORIN | 2 | 0.0005 |
| 6 | CEMIPLIMAB-RWLC | 1 | 0.0005 |
| 7 | DOSTARLIMAB | 1 | 0.0004 |
| 8 | SITAGLIPTIN PHOSPHATE | 1 | 0.0004 |
| 9 | DANAZOL | 1 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 145 | 0.0015 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 51 | 0.0011 |
| 3 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 2 | 0.0002 |
| 4 | Microtubule Inhibitor [EPC] | 28 | 0.0002 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 22 | 0.0001 |
| 6 | Programmed Death Ligand-1 Blocker [EPC] | 2 | 0.0001 |
| 7 | Platinum-based Drug [EPC] | 21 | 0.0001 |
| 8 | Androgen [EPC] | 1 | 0.0000 |
| 9 | Provitamin D2 Compound [EPC] | 1 | 0.0000 |